Showing 3861-3870 of 7858 results for "".
- Galderma Prices IPO; Will Start Trading on the Swiss Stock Exchange Todayhttps://practicaldermatology.com/news/galderma-prices-ipo-will-start-trading-on-the-swiss-stock-exchange-today/2462444/Dermatology leader Galderma Group announced the pricing of its initial public offering at CHF 53 ($59) per share in Switzerland. The shares will be listed and start trading under the ticker symbol “GALD” on the SIX Swiss Exchange, on March 22, 2024. At the recent A
- Review: Lack of Specificity Seen in Outcome Measurement Instruments Used for AE Reporting in Cancer Trialshttps://practicaldermatology.com/news/outcome-measurement-instruments-used-to-evaluate-dermatologic-adverse-events-in-cancer-trials/2462443/Some common measurement instruments of patient-reported outcomes in skin cancer trials lack specificity and rigorous validation, according to a new systematic review. "Assessment of type, severity, and impact of dermatologic adverse events (DAEs) necessitates well-developed and validated
- New Data on Long-Term Efficacy of Nemolizumab in Prurigo Nodularis and Its Durability in ADhttps://practicaldermatology.com/news/new-data-on-long-term-efficacy-of-nemolizumab-in-prurigo-nodularis-and-its-durability-in-ad-1/2462433/Galderma announced new data demonstrating nemolizumab’s long-term and increasing efficacy on skin lesions and other symptoms in prurigo nodularis through to week 52 in the OLYMPIA LTE study.[1] Additionally, data from the ARCADIA 1 and 2 trials in atopic dermatitis indicate that the majority of p
- INTEGUMENT-PED: Roflumilast Cream 0.05% Effective at Improving AD in Childrenhttps://practicaldermatology.com/news/integument-ped-roflumilast-cream-005-effective-at-improving-ad-in-children/2462429/New data from a pivotal phase 3 trial indicates roflumilast cream 0.05% is associated with significantly improved atopic dermatitis (AD) in children 2 to 5 years of age with mild-to-moderate AD. Researchers for the Interventional Trial Evaluating Roflumilast Cream for the Treatment of Ato
- Lebrikizumab Linked with Improvement in Patients with AD and Skin of Colorhttps://practicaldermatology.com/news/lebrikizumab-linked-with-improvement-in-patients-with-atopic-dermatitis-and-skin-of-color/2462431/New first-of-its-kind research presented at the American Academy of Dermatology 2024 Annual Meeting suggests that lebrikizumab showed efficacy in patients with skin of color who had atopic dermatitis (AD). “People with skin of color are disproportionately affected by AD, often experienci
- LITE: Home-based Narrow Band UVB Phototherapy for Psoriasis Non-Inferior to Office-based Treatmenthttps://practicaldermatology.com/news/lite-home-based-narrow-band-uv-b-phototherapy-for-psoriasis-noninferior-to-office-based-treatment/2462425/Home-based phototherapy for the treatment of psoriasis was non-inferior to office-based therapy, according to new data presented at the American Academy of Dermatology 2024 Annual Meeting in San Diego. Researchers for the Light Treatment Effectiveness (LITE) study, looking at whether home
- Bimekizumab Not Linked with Depression, Suicidal Ideation in Moderate-to-Severe Psoriasishttps://practicaldermatology.com/news/mental-health-outcomes-in-patients-with-moderate-to-severe-psoriasis-treated-with-bimekizumab-analysis-of-phase-23-randomized-trials/2462260/A new analysis indicates that bimekizumab was not associated with a high risk of suicidal ideation/behavior (SIB) and depression. Psoriasis patients often face increased risks of SIB and depression, according to the researchers. Bimekizumab, an FDA-approved biologic inhibiting
- Galderma to Showcase Latest Updates From Its Dermatology Portfolio at the 2024 AAD Annual Meetinghttps://practicaldermatology.com/news/galderma-to-showcase-latest-updates-from-its-dermatology-portfolio-at-the-2024-american-academy-of-dermatology-annual-meeting-1/2462259/Galderma will be showcasing its latest clinical and educational efforts at the American Academy of Dermatology (AAD) annual meeting from March 8-12, 2024, highlighting its dermatology portfolio. Galderma’s presence includes two late-breaking presentations on its first-in-class, investi
- Long-term Outcomes Impaired by Cutaneous Chronic Graft-vs-Host Diseasehttps://practicaldermatology.com/news/improved-melanoma-prognosis-with-31-gep/2462255/New analysis results indicate that cutaneous chronic graft-vs-host disease (GVHD) was linked with impaired long-term patient-reported outcomes (PROs). Researchers for the 9-center study conducted by the Chronic GVHD Consortium examined the association between different ty
- Analysis: Mix of Low- and Fair-quality Information for Hidradenitis Suppurativa Treatments on TikTokhttps://practicaldermatology.com/news/complementary-and-alternative-medicine-for-hidradenitis-suppurativa-discussed-on-tiktok-a-cross-sectional-analysis/2462251/Patients getting information on Hidradenitis suppurativa (HS) from TikTok were frequently exposed to low-quality information, a new study suggests. "Hidradenitis suppurativa (HS) is a painful, chronic inflammatory skin disease that negatively impacts quality of life," the